Le Viser Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 11-12-2024
- Paid Up Capital ₹ 5.48 M
as on 11-12-2024
- Company Age 20 Year, 3 Months
- Last Filing with ROC 31 Mar 2014
- Open Charges ₹ 8.40 M
as on 11-12-2024
- Satisfied Charges ₹ 1.58 Cr
as on 11-12-2024
About Le Viser Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2014. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.48 M.
The company currently has active open charges totaling ₹8.40 M. The company has closed loans amounting to ₹1.58 Cr, as per Ministry of Corporate Affairs (MCA) records.
Elangovan Swaminathan, Ramkumar, Pichaiah Nandakumar, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232TN2004PTC054177
- Company No.
054177
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 2004
- Date of AGM
30 Sep 2014
- Date of Balance Sheet
31 Mar 2014
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Le Viser Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Elangovan Swaminathan  | Managing Director | 08-Sep-2004 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ramkumar | Director | 08-Sep-2004 | Current |
| Pichaiah Nandakumar | Director | 08-Sep-2004 | Current |
| Backia Edward | Director | 08-Sep-2004 | Current |
| Shanmuga Singaram | Director | 08-Sep-2004 | Current |
Financial Performance of Le Viser Pharmaceuticals.
Enhance accessibility to Le Viser Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Le Viser Pharmaceuticals?
Unlock access to Le Viser Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Central Bank Of India Creation Date: 29 Apr 2015 | ₹8.40 M | Open |
Indian Bank Creation Date: 31 Dec 2009 | ₹1.58 Cr | Satisfied |
How Many Employees Work at Le Viser Pharmaceuticals?
Unlock and access historical data on people associated with Le Viser Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Le Viser Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Le Viser Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
